Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

New York-based, pharmaceutical giant Pfizer has made headlines recently with the announcement of a COVID-19 vaccine shown to be more than 90% effective in trials. This latest breakthrough is one of ...

Pfizer was among the drugmakers most elevated by the COVID-19 pandemic, and, going forward, the pharma giant has no plans to give up on its current momentum. Speaking this week at the J.P. Morgan ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue ...

Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

Pfizer's management knew last year there was "a mold issue" at the Kansas facility now slated to produce the drugmaker's urgently needed COVID-19 vaccine, according to a Food and Drug Administration ...

Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield.

London — England's National Health Service warned on Wednesday that people "with a history of a significant allergic reaction to a vaccine, medicine or food" should not be given the COVID-19 vaccine ...